Why This Popular Core Stock Is a Sell
When a great company’s stock is trading at a not-so-great price.
Karen Andersen, CFA
Karen Andersen, CFA, is a director for Morningstar.
More From Karen Andersen, CFA
AbbVie Earnings: Skyrizi Holds Steady Share Despite Competition
We think AbbVie stock is moderately overvalued.
Ahead of Earnings, Is Novo Nordisk Stock a Buy, a Sell, or Fairly Valued?
Investors will focus on the US launch of the Wegovy pill, 2026 guidance, and Novo’s rivalry with Eli Lilly.
Novo Nordisk: Alzheimer’s Failure Puts More Pressure on Oral Semaglutide Launch in Obesity
While disappointing, the failure of these trials was more likely than not, and we are not changing our fair value estimate.
Eli Lilly Earnings: International Tirzepatide Sales Outpaced Our Expectations
We’ve raised our fair value estimate of Lilly stock.
Novo Nordisk Earnings: CVS Deal, Oral Semaglutide Support Growth Despite Compounding Uncertainty
We think Novo Nordisk stock is undervalued.
US Healthcare: Policy Headwinds Continue to Weigh on the Sector, but Valuations Remain Attractive
Our top choices include Moderna and IQVIA.
Pfizer: Competitive Advantages Still Exist, but Signs of Erosion Lead Us to Lower Our Valuation
We’ve also reduced the firm’s moat rating from wide to narrow.
Novo Nordisk: CEO’s Surprise Departure Points to Challenging Obesity Market Dynamics
Leadership shake-up signals uncertainty amidst intensifying competition in obesity market.
Novo Nordisk: Shares Look Fairly Valued After CagriSema Disappointment
The firm’s history of reliable innovation and solid pipeline in cardiometabolic diseases continue to support a wide moat.
This 5-Star Stock With a Dividend Yield That Tops 4% Is a Buy
Undervalued by more than 30%, the stock of this wide-moat company looks like a bargain to us.
Undervalued by 28%, This Stock Is a Buy for Patient Investors
We think this wide-moat company is well positioned to drive growth beyond 2024.
